Balt Receives IDE Approval From the FDA to Begin the STEM Trial

IRVINE, Calif.–(BUSINESS WIRE)–Balt receives IDE approval from the FDA to begin the STEM Trial for the treatment of chronic Sub-Dural Hematoma (cSDH).